Stereotactic radiotherapy with immunotherapy or targeted therapy for metastatic kidney cancer
This study looked at the safety and effectiveness of targeted [...]
Pegilodecakin alone or in combination for heavily pre-treated advanced kidney cancer patients
This study looked at the use of pegilodecakin alone or [...]
Immune checkpoint inhibitors for sarcomatoid kidney cancer
Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive [...]
Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer
This Practice Update interview with Dr Monty Pal from City [...]
Nivolumab/cabozantinib combination recommended for EMA approval for first-line kidney cancer
The Committee for Medicinal Products for Human Use (CHMP) of [...]
ASCO GU 2021: Nivolumab plus cabozantinib combination for the first-line treatment of advanced kidney cancer
The past couple of years has seen a number of [...]
Effect of antibiotics on outcomes with systemic treatments for metastatic kidney cancer
The microbes in the gut (the gut microbiome) are a [...]
Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy
This study compared disease outcomes, treatments, and dose reductions in [...]
Surgery after targeted therapy or immunotherapy for metastatic kidney cancer
A recent retrospective study (looking back at the patients’ cases [...]
ESMO Virtual 2020: Cabozantinib plus atezolizumab in non-clear cell kidney cancer
Non-clear cell renal cell carcinoma (RCC) accounts for about 25% [...]
